Compare Ishares Msci Brazil ETF (EWZ) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ishares Msci Brazil ETF vs Pfizer Inc — how do they compare? Ishares Msci Brazil ETF trades at $42.96 (market cap $10.93B), while Pfizer Inc trades at $27.83 (market cap $159.59B). The key difference: Pfizer Inc is far larger — about 14.6× Ishares Msci Brazil ETF's market cap, and Pfizer Inc pays a 6.14% dividend while Ishares Msci Brazil ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ishares Msci Brazil ETF for 50 Days and Pfizer Inc for 158 Days on average.
| EWZ | PFE | |
|---|---|---|
Market Cap | $10.93B | $159.59B |
Volume | 45,143,031 | 30,937,010 |
Sector | Broad Market / Factor | Health |
52-Week High | $43.00 | $29.02 |
52-Week Low | $28.79 | $23.67 |
Typical Hold Time | 50 Days | 158 Days |
Enterprise Value | — | $211.09B |
Dividend Yield | — | 6.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWZ, the iShares MSCI Brazil ETF, trades at $42.37, down 1.47% today. The technical outlook is bullish based on moving averages but shows overbought signals with RSI readings above 70. Recent news highlights significant investor focus on Brazil's upcoming October election, with unusual options activity and institutional positioning indicating market anticipation of policy impacts.
The ETF offers diversification from U.S. markets with exposure to Brazilian commodities and financials. Key risks include election volatility and U.S. trade tariffs. Institutional buying and analyst views suggest cautious optimism, but high RSI levels warrant attention for near-term price pressure.
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ishares Msci Brazil ETF
EWZ is a country-specific ETF that tracks the Brazilian equity market. It provides exposure to large and mid-sized companies in Brazil, with a heavy focus on financials and materials, including major names like Nu Holdings, Vale, and Itaú Unibanco.
Read more on EWZ →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
